In La Rioja 14000 people are affectede
In La Rioja, 14,000 people are affected by chronic obstructive pulmonary disease.
Two million Spaniards, of whom 18,000 die every year are victims of one of the many practical jokes with which the snuff surprised many people with COPD.
Globally these figures exceeded 200 million as the number of people affected and about 3 million deaths caused by this disease, a chronic inflammation that causes structural changes and a progressive narrowing of the airways.
These figures justify, as has, mortal gold, been shown in Barcelona, the control of COPD is one of the main challenges for doctors and health authorities around the world, being now regarded as one of the major public health problems in industrialized countries. Underdiagnosis
Dr. Ruiz Manzano, chairman of SEPAR (Spanish Society of Pulmonology and Thoracic Surgery), estimated at 73 percent of patients suffering the disease and are not, ffxiv gil, diagnosed. "This is because over 90 percent of patients with COPD in Spain are attributed to smoking and symptoms (cough, expectoration of phlegm and breathlessness) to smoking and aging. In other words, is a misidentification of symptoms. "
Dr. Ruiz Manzano warns that, although an irreversible chronic disease is preventable and treatable. "With current drugs can control and greatly improved the quality of life," he says, and notes that "drugs are introduced orally, one way is always much easier and tolerated." In addition, states that "2 percent of the health budget is consumed by itself COPD."
latest developments
In this context, were presented during the, buy darkfall gold, conference different data on the first oral treatment designed specifically for COPD, roflumilast, a drug developed by Nycomed Pharma, which acts on the inflammation underlying the disease.
Conventional treatments for COPD are mainly aimed at treating the symptoms rather than the mechanisms that cause it.
Studies show that roflumilast, which has already been approved by European health authorities (EMEA) and is expected to be available in Spain in the coming months, increasing its benefits when given in conjunction with conventional therapies bronchodilator
Feeling of suffocation among patients
Exacerbations, or critical periods in which patients face serious difficulties in breathing, sudden worsening of the disease.
Patients feel suffocation and explain that crises can have permanent effects on their health and quality of life. May need antibiotics and steroids, and even get to enter the hospital.
Research with patients suggest that an exacerbation can be so distressing and perplexing as a heart attack. Even some patients who admit to having lost hope of returning to a normal life.
In fact, these episodes can threaten the patient's life. The potential to reduce exacerbations has roflumilast, addresses a clear unmet need in the current control of COPD.
The new data presented in Barcelona Roflumilast, show that patients who were administered the drug suffered fewer exacerbations comparedwith those who were administered placebo, and the elapsed time of an exacerbation to another was significantly longer.
The professor, Fernando Martinez, University of Michigan (USA), said "these results demonstrate that roflumilast provides a new therapeutic option to prevent exacerbations in COPD patients, particularly those who have them frequently."
COPD population has suffered "obvious unmet medical need despite currently available treatments," as says Dr. Izquierdo.
Therefore, insists that "it is necessary to further improve her lung function and quality of life, as well as reduce exacerbations whose rate remains high in many patients despite current therapies." For this part, the doctor adds that "roflumilast is effective and safe in these patients and can be used in addition to other medications."